Loading clinical trials...
Loading clinical trials...
Open-Label Phase 1b/2 Study of Cetuximab Administered in Combination With LY3214996 (ERK 1/2 Inhibitor) or Cetuximab in Combination With LY3214996 and Abemaciclib in Patients With Metastatic, Anti-EGFR-Refractory Colorectal Cancer
Conditions
Interventions
Abemaciclib
Cetuximab
+1 more
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
December 2, 2020
Primary Completion Date
December 31, 2028
Completion Date
December 31, 2028
Last Updated
December 23, 2025
NCT04693377
NCT05863195
NCT04704661
NCT06349642
NCT07463599
NCT07224724
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions